Literature DB >> 27344205

Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.

Paul J Hoover1, Karen H Costenbader2.   

Abstract

Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus that disproportionately affects nonwhites and those in lower socioeconomic groups. This review discusses recent data on the incidence, prevalence, and outcomes of patients with lupus nephritis with a focus on low-income US Medicaid patients. We also review recent guidelines on diagnosis, treatment, and screening for new onset and relapses of lupus nephritis. Finally, we discuss the management of lupus nephritis from a rheumatologist's perspective, including vigilance for the common adverse events related to disease and treatment, and we review prevention and new treatment strategies.
Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  epidemiology; glomerulonephritis; lupus

Mesh:

Substances:

Year:  2016        PMID: 27344205      PMCID: PMC5679458          DOI: 10.1016/j.kint.2016.03.042

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  46 in total

1.  Report on the Fifth African League Against Rheumatism Congress in Nairobi, Kenya.

Authors:  George O Oyoo; Girish M Mody
Journal:  Clin Rheumatol       Date:  2007-04-19       Impact factor: 2.980

2.  Regional distribution of adult rheumatologists.

Authors:  John D FitzGerald; Michael Battistone; Calvin R Brown; Amy C Cannella; Eliza Chakravarty; Allan C Gelber; Carlos J Lozada; Marilynn Punaro; Barbara Slusher; Abby Abelson; David A Elashoff; LaTanya Benford
Journal:  Arthritis Rheum       Date:  2013-12

3.  Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program.

Authors:  Emily C Somers; Wendy Marder; Patricia Cagnoli; Emily E Lewis; Peter DeGuire; Caroline Gordon; Charles G Helmick; Lu Wang; Jeffrey J Wing; J Patricia Dhar; James Leisen; Diane Shaltis; W Joseph McCune
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

4.  The incidence and prevalence of systemic lupus erythematosus, 2002-2004: The Georgia Lupus Registry.

Authors:  S Sam Lim; A Rana Bayakly; Charles G Helmick; Caroline Gordon; Kirk A Easley; Cristina Drenkard
Journal:  Arthritis Rheumatol       Date:  2014-02       Impact factor: 10.995

Review 5.  Clinical presentation and monitoring of lupus nephritis.

Authors:  J E Balow
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

7.  Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004.

Authors:  Candace H Feldman; Linda T Hiraki; Jun Liu; Michael A Fischer; Daniel H Solomon; Graciela S Alarcón; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Rheum       Date:  2013-03

Review 8.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

9.  Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions.

Authors:  N Hiramatsu; T Kuroiwa; H Ikeuchi; A Maeshima; Y Kaneko; K Hiromura; K Ueki; Y Nojima
Journal:  Rheumatology (Oxford)       Date:  2008-04-04       Impact factor: 7.580

10.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103

View more
  19 in total

1.  Factors influencing implementation of a computerized, individualized, culturally tailored lupus decision aid in lupus clinics: a qualitative semi-structured interview study.

Authors:  Haiyan Qu; Xuejun Hu; Jasvinder A Singh
Journal:  Clin Rheumatol       Date:  2019-06-20       Impact factor: 2.980

2.  Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies.

Authors:  Cianna Leatherwood; Cameron B Speyer; Candace H Feldman; Kristin D'Silva; José A Gómez-Puerta; Paul J Hoover; Sushrut S Waikar; Gearoid M McMahon; Helmut G Rennke; Karen H Costenbader
Journal:  Semin Arthritis Rheum       Date:  2019-06-11       Impact factor: 5.532

3.  Spectrum of Morphological and Immunofluorescence Patterns in Lupus Nephritis: A Single Institutional Study.

Authors:  Saira Javeed; Safana Sadaf; Saima Batool; Ayma Batool; Zubaria Rafique; Akhtar S Chughtai
Journal:  Cureus       Date:  2022-05-26

Review 4.  Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy.

Authors:  Naomi I Maria; Anne Davidson
Journal:  Nat Rev Rheumatol       Date:  2020-03-19       Impact factor: 20.543

Review 5.  Reproductive health and pregnancy in women with chronic kidney disease.

Authors:  Kate S Wiles; Catherine Nelson-Piercy; Kate Bramham
Journal:  Nat Rev Nephrol       Date:  2018-01-22       Impact factor: 28.314

6.  A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.

Authors:  Rachael D Wright; Fariba Bannerman; Michael W Beresford; Louise Oni
Journal:  BMC Nephrol       Date:  2020-06-30       Impact factor: 2.388

Review 7.  Disparities in Lupus and Lupus Nephritis Care and Outcomes Among US Medicaid Beneficiaries.

Authors:  Katherine P Pryor; Medha Barbhaiya; Karen H Costenbader; Candace H Feldman
Journal:  Rheum Dis Clin North Am       Date:  2020-10-29       Impact factor: 2.670

8.  Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy.

Authors:  Homa Timlin; Laurence Magder; Michelle Petri
Journal:  Cureus       Date:  2017-12-04

9.  Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-γ monoclonal antibody, in SLE subjects without or with lupus nephritis.

Authors:  Michael J Boedigheimer; David A Martin; Zahir Amoura; Jorge Sánchez-Guerrero; Juanita Romero-Diaz; Alan Kivitz; Cynthia Aranow; Tak Mao Chan; Yip Boon Chong; Kit Chiu; Christine Wang; Winnie Sohn; Gregory E Arnold; Michael A Damore; Andrew A Welcher; Barbara A Sullivan; Brian L Kotzin; James B Chung
Journal:  Lupus Sci Med       Date:  2017-09-14

Review 10.  Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations.

Authors:  Myrto Kostopoulou; Antonis Fanouriakis; Kim Cheema; John Boletis; George Bertsias; David Jayne; Dimitrios T Boumpas
Journal:  RMD Open       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.